Tackling cancer waiting times requires consistent leadership and
relentless focus, Health Minister has said.
Noting the latest Northern Ireland Cancer Waiting Times figures,
the Minister said they showed the scale of the challenge ahead.
said: Behind every figure is
a person waiting for answers and a family living with
uncertainty. A suspected cancer diagnosis can be frightening, and
I understand how distressing it is when people then face a long
wait for assessment or treatment.
Today's figures show the scale of the challenge before us. Whilst
there has been great progress made on tackling elective waiting
times and innovations in cancer treatments are constantly
improving, the overall waiting times position for cancer is not
acceptable.
However, there are some important indications of improvement. The
figures for breast cancer show that the median wait has fallen
from 56 days in September 2025 to 38 days in June 2026. As part
of a more regional focus on those waiting times, we have invested
£5 million through the Elective Care Framework, established a
regional Breast Operational Delivery Network and are using
additional clinic capacity to help address the backlog. These
steps are imperative to improving access.
There is no doubt that there is still much more to do. As a new
Minister, I want to explore what opportunity exists to do more
and drive further improvement more rapidly. This work needs
consistent leadership and relentless focus. Today's cancer
waiting times underline the importance of political stability,
and why we must all remain steadfast on tackling the challenges
facing our health service. Patients and staff need that sustained
commitment to improve cancer care.
The Minister added: The Elective Care Framework (ECF) remains the
roadmap for tackling our cancer waits on a sustainable
basis. In line with the ECF, Programme for Government
funding has been targeted at reducing waits for cancer
diagnostics and treatment. This includes investment in
endoscopy, imaging, workforce, phlebotomy and across multiple
specialties.
In addition to this targeted investment, we are actively
understanding, managing and improving whole cancer pathways
through structured review, shared learning and strengthened
accountability.